Spruck C - Search Results

1

Triple‑negative breast cancer therapy: Current and future perspectives (Review).

Won KA, Spruck C. Won KA, et al. Among authors: spruck c. Int J Oncol. 2020 Dec;57(6):1245-1261. doi: 10.3892/ijo.2020.5135. Epub 2020 Oct 16. Int J Oncol. 2020. PMID: 33174058 Free PMC article. Review.

2

Deregulated cyclin E induces chromosome instability.

Spruck CH, Won KA, Reed SI. Spruck CH, et al. Nature. 1999 Sep 16;401(6750):297-300. doi: 10.1038/45836. Nature. 1999. PMID: 10499591

3

Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.

Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Strohmaier H, et al. Among authors: spruck ch. Nature. 2001 Sep 20;413(6853):316-22. doi: 10.1038/35095076. Nature. 2001. PMID: 11565034

4

A FBXO7/EYA2-SCF^FBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells.

Shen JZ, Qiu Z, Wu Q, Zhang G, Harris R, Sun D, Rantala J, Barshop WD, Zhao L, Lv D, Won KA, Wohlschlegel J, Sangfelt O, Laman H, Rich JN, Spruck C. Shen JZ, et al. Among authors: spruck c. Mol Cell. 2022 Mar 17;82(6):1123-1139.e8. doi: 10.1016/j.molcel.2022.01.022. Epub 2022 Feb 18. Mol Cell. 2022. Retraction in: Mol Cell. 2024 Jun 20;84(12):2398. doi: 10.1016/j.molcel.2024.05.022. PMID: 35182481 Free PMC article. Retracted.

5

PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.

Brunner A, Suryo Rahmanto A, Johansson H, Franco M, Viiliäinen J, Gazi M, Frings O, Fredlund E, Spruck C, Lehtiö J, Rantala JK, Larsson LG, Sangfelt O. Brunner A, et al. Among authors: spruck c. Elife. 2020 Jul 6;9:e57894. doi: 10.7554/eLife.57894. Elife. 2020. PMID: 32628111 Free PMC article.

6

FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells.

Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, Sangfelt O, Bradley LM, Wohlschlegel J, Rich JN, Spruck C. Shen JZ, et al. Among authors: spruck c. Cell. 2021 Jan 21;184(2):352-369.e23. doi: 10.1016/j.cell.2020.11.042. Epub 2020 Dec 23. Cell. 2021. PMID: 33357448 Free PMC article.

7

PP2A-B55β antagonizes cyclin E1 proteolysis and promotes its dysregulation in cancer.

Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AA, Wohlschlegel J, Widschwendter M, Spruck C. Tan Y, et al. Among authors: spruck c. Cancer Res. 2014 Apr 1;74(7):2006-14. doi: 10.1158/0008-5472.CAN-13-1263. Epub 2014 Feb 7. Cancer Res. 2014. PMID: 24509904 Free PMC article.

8

Cks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints.

del Rincón SV, Widschwendter M, Sun D, Ekholm-Reed S, Tat J, Teixeira LK, Ellederova Z, Grolieres E, Reed SI, Spruck C. del Rincón SV, et al. Among authors: spruck c. Oncogene. 2015 Apr 9;34(15):1961-7. doi: 10.1038/onc.2014.137. Epub 2014 May 26. Oncogene. 2015. PMID: 24858038 Free PMC article.

9

F-box proteins in epigenetic regulation of cancer.

Shen J, Spruck C. Shen J, et al. Among authors: spruck c. Oncotarget. 2017 Nov 16;8(66):110650-110655. doi: 10.18632/oncotarget.22469. eCollection 2017 Dec 15. Oncotarget. 2017. PMID: 29299176 Free PMC article. Review.

10

CKS protein overexpression renders tumors susceptible to a chemotherapeutic strategy that protects normal tissues.

Tat J, Loriot C, Henze M, Spruck C, Felding BH, Reed SI. Tat J, et al. Among authors: spruck c. Oncotarget. 2017 Dec 4;8(70):114911-114923. doi: 10.18632/oncotarget.22931. eCollection 2017 Dec 29. Oncotarget. 2017. PMID: 29383129 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters